Scarica l'app Stockscreener
34.04
1.25%
0.42
Dopo l'orario di chiusura:
33.88
-0.16
-0.47%
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. - Stock Titan
Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares. - Stock Titan
CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes. - Stock Titan
Vesting triggers withholding of 46,879 shares from Roivant Sciences (ROIV) President Mayukh Sukhatme. - Stock Titan
After exercising $3.85 options, Eric Venker sells shares in Roivant Sciences (ROIV). - Stock Titan
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Nigeria
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant (ROIV) director uses shares to cover taxes - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches - TradingView
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com India
Why Did Roivant (NASDAQ:ROIV) Shares Surge on Study Results? - Kalkine Media
Roivant Sciences Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $46 to $55 - Moomoo
ROIV Maintains Buy Rating -- Price Target Raised to $55 - GuruFocus
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
Guggenheim raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com Australia
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com Australia
H.C. Wainwright raises Roivant Sciences price target on trial data - investing.com
Guggenheim raises Roivant Sciences stock price target on trial data - Investing.com
Roivant Sciences Stock Rallies 20% On Positive Phase 2 Trial Results For Pulmovant Drug - TIKR.com
Roivant Sciences stock surges on positive PH-ILD trial data By Investing.com - Investing.com Australia
2.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):